Bosnia adds new therapies to list but access doubts persist

The FBiH government announced an expanded list of reimbursed therapies, but patient groups warn that practical access remains limited. The gap between policy and implementation is the key uncertainty, with no details on funding or distribution. This matters because it affects treatment availability for chronic and rare diseases in the region.